mAbxience Announces European Commission Approval of Denosumab Biosimilars

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

MABXIENCE-EU-approval

More Like This

PR Newswire associated0

Advancing Bone Health: European Commission Approves Biocon Biologics' Denosumab Biosimilars

PR Newswire associated0

Bone Health: Biocon Biologics Receives Positive CHMP Opinions for Biosimilar Denosumab in Europe

Samsung Bioepis Gains European Commission (EC) Approval for Denosumab Biosimilar (OBODENCE™, XBRYK™)

Celltrion Expands Biosimilar Portfolio in the European Union Following European Commission Approval of Two Biosimilars

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®

PR Newswire associated0

mAbxience Appoints Jurgen Van Broeck as New CEO

European Commission (EC) Approves Henlius and Organon’s BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

mAbxience and Biosidus Sign CDMO Agreement for the Manufacture of Agalsidase Beta for the Treatment of Fabry Disease